

Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and β -Pancreatic Cells and in Obesity and Hyperglycemia

Isabel Matias, Marie-Paule Gonthier, Pierangelo Orlando, Vassilis Martiadis, Luciano De Petrocellis, Cristina Cervino, Stefania Petrosino, Laurence Hoareau,* Franck Festy,* Renato Pasquali, Regis Roche,* Mario Maj, Uberto Pagotto, Palmiero Monteleone, and Vincenzo Di Marzo

Endocannabinoid Research Group (I.M., P.O., L.D.P., S.P., V.D.M.) at the Institutes of Biomolecular Chemistry (I.M., S.P., V.D.M.), Biochemistry of Proteins (P.O.), and Cybernetics (L.D.P.), National Research Council, 80078 Pozzuoli (NA), Italy; Université de La Réunion (M.-P.G., L.H., F.F., R.R.), 97715 La Réunion, France; Department of Psychiatry (V.M., M.M., P.M.), Second University of Naples, 80138 Naples, Italy; and Endocrinology Unit (C.C., R.P., U.P.), Department of Internal Medicine and Gastroenterology, Center of Applied Biomedical Research, S. Orsola-Malpighi General Hospital, 40138 Bologna, Italy

Context: Cannabinoid CB₁ receptor blockade decreases weight and hyperinsulinemia in obese animals and humans in a way greatly independent from food intake.

Objective: The objective of this study was to investigate the regulation and function of the endocannabinoid system in adipocytes and pancreatic β -cells.

Design, Setting, and Patients: Mouse 3T3-F442A adipocytes and rat insulinoma RIN-m5F β -cells, pancreas and fat from mice with diet-induced obesity, visceral and sc fat from patients with body mass index equal to or greater than 30 kg/m², and serum from normoglycemic and type 2 diabetes patients were studied.

Main Outcome Measure: Endocannabinoid enzyme and adipocyte protein expression, and endocannabinoid and insulin levels were measured.

Results: Endocannabinoids are present in adipocytes with levels peaking before differentiation, and in RIN-m5F β -cells, where they

are under the negative control of insulin. Chronic treatment of adipocytes with insulin is accompanied by permanently elevated endocannabinoid signaling, whereas culturing of RIN-m5F β -cells in high glucose transforms insulin down-regulation of endocannabinoid levels into up-regulation. Epididymal fat and pancreas from mice with diet-induced obesity contain higher endocannabinoid levels than lean mice. Patients with obesity or hyperglycemia caused by type 2 diabetes exhibit higher concentrations of endocannabinoids in visceral fat or serum, respectively, than the corresponding controls. CB₁ receptor stimulation increases lipid droplets and decreases adiponectin expression in adipocytes, and it increases intracellular calcium and insulin release in RIN-m5F β -cells kept in high glucose.

Conclusions: Peripheral endocannabinoid overactivity might explain why CB₁ blockers cause weight-loss independent reduction of lipogenesis, of hypoadiponectinemia, and of hyperinsulinemia in obese animals and humans. (*J Clin Endocrinol Metab* 91: 3171–3180, 2006)

THE ENDOCANNABINOID SYSTEM comprises two cannabinoid receptor subtypes, CB₁ and CB₂, their endogenous ligands [the endocannabinoids, anandamide and 2-arachidonoylglycerol (2-AG)], and enzymes for ligand biosynthesis and degradation, *i.e.* the *sn*-1-selective diacylglycerol- α lipase (DAGL- α), the monoacylglycerol lipase (MAGL), the *N*-arachidonoylphosphatidylethanolamine phospholipase D (NAPE-PLD), and the fatty acid amide hydrolase (FAAH) (1). Although discovered relatively recently, this signaling system has already provided a drug for the

treatment of obesity: rimonabant, a selective CB₁ antagonist (2, 3). In fact, it is known that blockade of CB₁ receptors causes reduction of food intake in food-deprived lean animals, and in *ad lib*-fed obese animals (2, 4–6). Like other orexigenic mediators, hypothalamic endocannabinoids are subject to negative regulation by leptin and are permanently elevated in genetically obese rodents, in which they contribute to hyperphagia (7–9). However, it is also clear that the persistent weight loss that follows chronic blockade of CB₁ receptors is largely independent from its transient inhibition of food intake (5, 10, 11). CB₁-deficient mice exhibit significantly less fat mass than wild-type mice and are not susceptible to developing obesity after a high-fat diet, even when they consume as much food as wild types (12, 13). These findings suggest that the endocannabinoid system contributes to obesity via peripheral mechanisms, possibly by being permanently up-regulated, as recently shown in the liver of mice with diet-induced obesity (DIO) (14). Chronic blockade of CB₁ receptors in obese animals and humans also reduces, when present, the signs of the “metabolic syndrome” as first

First Published Online May 9, 2006

* L.H., F.F., and R.R. contributed equally to this work.

Abbreviations: 2-AG, 2-Arachidonoylglycerol; BMI, body mass index; DAGL- α , *sn*-1-selective diacylglycerol- α lipase; DIO, diet-induced obesity; FAAH, fatty acid amide hydrolase; IBMX, 3-isobutyl-1-methylxanthine; MAGL, monoacylglycerol lipase; NAPE-PLD, *N*-arachidonoylphosphatidylethanolamine phospholipase D; PPAR- γ , peroxisome proliferator-activated receptor γ .

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

defined by the National Cholesterol Education Program Adult Treatment Panel III (15), *i.e.* high waist circumference (abdominal obesity), high triglyceridemia, low high-density lipoprotein cholesterol, high mean arterial pressure, and high fasting glycemia (and subsequent hyperinsulinemia) (10, 11, 16). Yet, it is not known whether these additional beneficial effects are merely the consequence of weight loss or also the result of peripheral actions of CB₁ blockers exerted directly on cells involved in lipogenesis and insulin production, *i.e.* white adipocytes and pancreatic islet β -cells, respectively. White adipocytes do express functional CB₁ receptors, whose levels are higher in obese rats and whose blockade leads to increased levels of adiponectin (13, 17), an adipokine that enhances insulin sensitivity and glucose and lipid metabolism (18). Pancreatic islets also express cannabinoid receptors (19). However, it is not known whether endocannabinoids are present in adipocytes or pancreatic β -cells, nor whether they directly contribute to lipogenesis and hyperinsulinemia during obesity and hyperglycemia. Thus, we investigated the function and possible dysregulation of endocannabinoids in isolated adipocytes and β -cells cultured under conditions mimicking either normal or unbalanced energy homeostasis, and in adipose tissue, pancreas, and serum of DIO mice and obese or type 2 diabetic hyperglycemic patients.

Subjects and Methods

Cell cultures

The mouse preadipocyte 3T3-F442A cell line (fifth to 10th passage) was kindly provided by Dr. Mohamed Bensaid from Sanofi-Aventis (Montpellier, France). 3T3-F442A preadipocytes were grown according to the manufacturer's recommendations. After confluence, 3T3-F442A adipose differentiation was obtained in the presence of the same culture medium supplemented with 0.9 μ M insulin. Cells were placed into culture (d -6) and grown to confluence (d -2) before stimulation with insulin (d 0). Terminal differentiation occurred by d 12. Differentiation was also induced with a mixture of 3-isobutyl-1-methylxanthine (IBMX; 0.5 mM), dexamethasone (1 mM), and insulin (0.9 μ M). For adipocyte stimulation, HU210 (100 nM), rimonabant (SR141716A or SR1, 100 nM), SR144528 (SR2, a selective cannabinoid CB₂ receptor antagonist, 100 nM), leptin (20 nM), and ciglitazone [a peroxisome proliferator-activated receptor γ (PPAR- γ) agonist, 20 μ M] were added in dimethyl sulfoxide (final concentration 0.1%) to the culture medium. For experiments on cAMP, confluent 3T3-F442A mature adipocytes were plated in six-well dishes and stimulated for 10 min at 37 C with 1 μ M forskolin in 400 μ l serum-free recommended medium containing 20 mM HEPES, 0.1 mg/ml BSA, and 0.1 mM IBMX. Cells were treated with vehicle, or HU-210 (20 or 200 nM), or with SR1 (200 nM) or with HU-210 + SR1 (200 nM each). After incubation, cAMP cellular content was determined by means of a cAMP assay kit (Amersham, Buckinghamshire, UK).

RIN-m5F rat insulinoma β -pancreatic cells were obtained from ATCC and grown according to the manufacturer's recommendations. For ex-

periments with cells in low and high glucose conditions, cells were grown in the recommended culture medium containing respectively 2.4 g/liter glucose (13 mM) and 4.5 g/liter glucose (25 mM) for 24 h before experiments. For RIN-m5F cell stimulation, leptin (20 nM), insulin (100 nM), HU210 (200 nM), rimonabant (1 μ M), and SR144528 (1 μ M) were added in dimethyl sulfoxide (final concentration 0.1%) to the culture medium depleted in fetal calf serum. In these cells, the effect of HU-210 (50, 100, 1000, and 5000 nM) on intracellular Ca²⁺ in the presence or absence of SR1 (200 nM) was measured by means of Fluo-4 or Fura-2 fluorometric detection.

Insulin release quantification

Insulin release from RIN-m5F rat β -cells was quantified in the cell media by ELISA (Mercodia) realized by Biovendo (Modrice, Republic Tchegue).

Oil Red-O staining

Light microscopy and Oil Red-O staining were used to monitor the characteristic cell rounding and lipid droplet accumulation in these cells during differentiation (20).

Animals

Male lean and DIO C57BL/6J mice and ICR mice with streptozotocin-induced diabetes (21) were anesthetized and decapitated. DIO mice were obtained by feeding lean C57BL/6J mice with an increased fat diet (from 9 to 20% fat content) for 8 wk. Pancreas and epididymal fat mass were removed and immediately frozen in liquid nitrogen until quantitative determination of endocannabinoids. Blood was collected to determine leptin and insulin levels using RIA kits from Linco. Guidelines for the use and care of laboratory animals of the authors' institutions were followed.

Subjects and blood or fat sampling

Visceral/sc fat from normoweight and overweight/obese volunteers was collected during Roux-en-Y gastric Bypass surgery for all 20 obese patients, and during colecystectomy (n = 4) and hiatal hernias removal (n = 6) for the normoweight controls (Table 1). Samples were immediately frozen in liquid nitrogen until endocannabinoid quantification. Blood from patients with type 2 diabetes and age-matched healthy volunteers was collected between 0800 and 0900 h, the last treatment having been done not earlier than 12 h before blood sampling (Table 2). Regarding the determination of circulating preprandial and postprandial endocannabinoid levels, 12 healthy human subjects (eight males, four females) were recruited [age = 32.3 \pm 3.9 yr; body mass index (BMI) = 21.7 \pm 2.9 kg/m², means \pm SD]. After a 12-h fasting period, volunteers received a high-fat meal providing 601.12 kcal and consisting of 16.6% protein, 39.25% carbohydrate, and 44.15% fat. Preprandial and postprandial blood samples were collected 1 h before and after the test meal, respectively. All patients and volunteers were informed of the study procedures and signed an informed consent.

Purification and quantification of endocannabinoids

The extraction, purification, and quantification of anandamide and 2-AG from tissues, blood, and cells was performed as described previ-

TABLE 1. Obese *vs.* normoweight patients

	Age (yr)	BMI (kg/m ²)	Gender	Glucose (mmol/liter)	Fat mass (kg)	Lean mass (kg)
Normoweight volunteers (n = 10) mean \pm SE	56.7 \pm 5.9	21.3 \pm 0.3	4 male/6 female	4.83 \pm 0.17	14.9 \pm 2.7	43.6 \pm 4.8
Obese patients (n = 20) mean \pm SE	45.9 \pm 2.1 ^a	45.1 \pm 1.8 ^b	9 male/11 female	5.67 \pm 0.11 ^c	59.5 \pm 17.2 ^b	47.1 \pm 12.1

None of the patients was under pharmacological treatment at the time of surgery. Fat and lean mass was assessed by bioimpedometric analyses.

^a $P < 0.05$ *vs.* normoweight volunteers, as assessed by the Kuskal-Wallis nonparametric test.

^b $P < 0.0005$ *vs.* normoweight volunteers, as assessed by the Kuskal-Wallis nonparametric test.

^c $P < 0.005$ *vs.* normoweight volunteers, as assessed by the Kuskal-Wallis nonparametric test.

TABLE 2. Type 2 diabetic *vs.* healthy volunteers

	Age (yr)	BMI (kg/m ²)	Gender	Glucose (mmol/liter)	Cholesterol (mmol/liter)	Triglycerides (mmol/liter)
Healthy volunteers (n = 8) mean ± SE	62.3 ± 2.4	28.6 ± 1.9	5 male/3 female	5.72 ± 0.22	4.56 ± 0.56	0.93 ± 0.10
Diabetic patients (n = 10) mean ± SE	69.0 ± 4.0	33.5 ± 3.0	4 male/6 female	10.28 ± 1.17 ^a	5.95 ± 0.97 ^b	2.00 ± 0.25 ^a

This experiment was designed to assess whether or not a noncorrected hyperglycemia, due to a pathological condition, results in increased serum endocannabinoid levels. For this reason we used patients with type 2 diabetes with randomized pharmacological treatments. In fact, of the 10 patients, two were under treatment with metformin, one with metformin + insulin, one with glibenclamide, two with metformin + glibenclamide, one with acarbose + glibenclamide, and three with insulin only. In each case, the last treatment was given not later than 12 h prior to blood sampling. As shown in the table, this heterogeneity in treatment resulted in similar fasting glycemia values.

^a $P < 0.005$, *vs.* healthy volunteers, as assessed by the Kuskal-Wallis nonparametric test.

^b $P < 0.001$, *vs.* healthy volunteers, as assessed by the Kuskal-Wallis nonparametric test.

ously (22). After extraction, endocannabinoid fractions were subjected to isotope-dilution liquid chromatography-atmospheric pressure chemical ionization-mass spectrometric analysis as previously described (22).

Statistical analysis

All results were expressed as mean ± SEM. The statistical significance of differences in mean values was assessed by one-way ANOVA followed by the Bonferroni's *post hoc* analysis, or by the Kruskal-Wallis nonparametric test in the case of human samples.

Real-time RT-PCR analyses

Real-time cDNA quantification was performed by a thermocycler iCycler iQ (Bio-Rad, Hercules, CA). Fluorescence data were collected during elongation. Optimized PPAR- γ , adiponectin, CB₁, CB₂, FAAH, NAPE-PLD, DAGL- α , and MAGL primers for SYBR Green analysis (and relative TaOpt), were designed by "Beacon Designer" software and synthesized by MWG-Biotech AG (Ebersberg, Germany). Assays were performed in triplicate (SD of threshold cycle mean < 0.5) and a standard curve from consecutive 5-fold dilutions (150–0.24 ng) of a cDNA pool representative of all samples, was included for each determination. Relative expression analysis correct for PCR efficiency and normalized respect to reference genes β -actin and hypoxanthine phosphoribosyltransferase was performed by "REST C" software for group-wise comparison and statistical analysis.

Results

Regulation of the endocannabinoid system during adipocyte differentiation

Mouse 3T3 F442A preadipocytes were differentiated into adipocytes using conditions mimicking hyperinsulinemia, with a high concentration of insulin, either alone or in a mixture with IBMX and dexamethasone. Differentiation was monitored by measuring PPAR- γ expression by real-time PCR (fold enhancement over d 0) and Oil Red-O staining of lipid droplets, and occurred more rapidly with insulin alone (Fig. 1A). PPAR- γ expression was significantly different from d 0 on d 8 and 12 under both conditions. Note the full cell rounding occurring already at d 8 with insulin only, and the increased formation of lipid droplets (red dots, *black* in Fig. 1A) between d 8 and 12. Basal and forskolin-induced cAMP levels were also increased 3.5 ± 0.2- and 3.0 ± 0.3-fold at d 8 *vs.* d 0. Adiponectin expression was increased 5.9 ± 0.6-fold at d 12 *vs.* d 0 (data not shown, means ± SE). Irrespective of the type of stimulation, adipocyte differentiation was preceded by a 2.5- to 7-fold enhancement of the levels of the two endocannabinoids, anandamide and 2-AG, the latter of which remained strongly elevated in mature (d 8) and hypertrophic (d 12) adipocytes (Fig. 1B). In fact, although peaks of 2-AG levels were seen, depending on the stimulus, at d 4 or 8, there was no statistically significant difference in 2-AG

levels between d 4, 8, and 12. Accordingly, differentiation was accompanied by a dramatic increase of the expression of the 2-AG biosynthesizing enzyme, the DAGL- α (1), whereas the 2-AG-degrading enzyme, MAGL, was unchanged (Fig. 1C). The expression level of the anandamide biosynthesizing enzyme, NAPE-PLD, decreased during differentiation and was 1.25 ± 0.01-, 1.37 ± 0.01-, and 0.85 ± 0.01-fold *vs.* d 0 at d 4, 8, and 12, respectively, whereas that of the anandamide-degrading enzyme, FAAH, instead increased by going from 0.96 ± 0.04- to 1.31 ± 0.04- and 1.36 ± 0.03-fold *vs.* d 0 at d 4, 8, and 12, respectively (means ± SE, n = 4) (data not shown). These changes might explain why anandamide levels peaked at d 4 and decreased thereafter. CB₁ and CB₂ receptors were strongly expressed only in differentiating adipocytes and remained expressed in mature cells (Fig. 1C). CB₁ levels slightly decreased in hypertrophic *vs.* partially differentiated preadipocytes (d 8–12 *vs.* d 4).

Regulation of endocannabinoid levels by leptin and PPAR- γ

As previously reported in the rodent hypothalamus, lymphocytes, and uterus (7, 23, 24), both anandamide and 2-AG levels in mature adipocytes (d 8, with insulin only) were decreased after either acute (1 h) or prolonged (24 h) stimulation with leptin (20 nM) (Fig. 1D). In partially differentiated preadipocytes (d 4, with insulin only), leptin (20 nM, 1 h) decreased anandamide levels (from 5.7 ± 0.1 to 3.6 ± 0.4 pmol/mg lipid extract, n = 4, $P < 0.01$), but not 2-AG levels (from 41.0 ± 4.2 to 44.1 ± 5.5 pmol/mg lipid extract, n = 4). Ciglitazone (20 μ M, 24 h), a selective agonist of PPAR- γ , decreased 2-AG, but not anandamide, levels in partially differentiated preadipocytes (d 4) (from 37.0 ± 7.0 to 13.4 ± 1.4 pmol/mg lipid extract, n = 4, $P < 0.05$), but not in mature adipocytes (d 8) (from 21.0 ± 2.2 to 22.2 ± 2.5 pmol/mg lipid extract, n = 4).

Effect of CB₁ stimulation on PPAR- γ and adiponectin expression and lipid levels in adipocytes

Chronic activation of cannabinoid receptors with HU-210 stimulated an early marker of adipocyte differentiation, PPAR- γ , at d 8, and inhibited adiponectin expression, a late marker of differentiation, only at d 12 (Fig. 2B). These effects were attenuated or reversed by rimonabant. HU-210 (200 nM) stimulated the accumulation of lipid droplets at d 8. The number of Oil Red-O-stained droplets per square millimeter (in *black* in Fig. 2A) were 7,590 ± 310, 11,670 ± 470, 6,830 ± 90, and 9,170 ± 540 with vehicle, HU-210 ($P < 0.01$ *vs.*




FIG. 1. Regulation and role of the endocannabinoid system during adipocyte differentiation. A, Differentiation of mouse 3T3 F442A preadipocytes into adipocytes was monitored by measuring PPAR- γ expression by real-time RT-PCR (lower panel), or Oil Red-O staining under a microscope (upper panel, insulin only). mRNA expression is expressed as fold enhancement over d 0. Error bars are not shown, and they were always equal to or less than 10%. SD values for cycle threshold were always less than 1%. *, **, $P < 0.05$, 0.01 vs. d 0, respectively, as assessed by ANOVA followed by the Bonferroni's test. B, Levels of endocannabinoids during adipocyte differentiation induced with insulin alone ($0.9 \mu\text{M}$) or in a mixture with IBMX (0.5 mM) and dexamethasone (1.0 mM). Endocannabinoid levels were measured by isotope-dilution liquid chromatography-mass spectrometry (see *Subjects and Methods*). Data are means \pm SE of $n = 3$ –6 separate experiments. *, **, ***, $P < 0.05$, 0.01 , 0.005 vs. vehicle, respectively, as assessed by ANOVA followed by the Bonferroni's test. C, Effect of chronic stimulation with insulin alone ($0.9 \mu\text{M}$) on the expression of CB $_1$, CB $_2$, DAGL- α , and MAGL, as measured by real-time RT-PCR (fold enhancement over d 0). Error bars are not shown because they were always equal to or less than 10%. SD values for cycle threshold were always less than 1%. *, **, ***, $P < 0.05$, 0.01 , 0.005 vs. d 0, respectively; #, $P < 0.05$ vs. d 4, as assessed by ANOVA followed by the Bonferroni's test. D, Effect on endocannabinoid levels of acute (1 h) or prolonged (24 h) stimulation with leptin (20 nM) of differentiated adipocytes (d 8, insulin only). Data are means \pm SE of $n = 4$ –6 separate experiments. *, **, $P < 0.05$, 0.01 vs. vehicle, respectively, as assessed by ANOVA followed by the Bonferroni's test.

vehicle), HU-210 plus rimonabant ($P < 0.01$ vs. HU-210) and rimonabant alone ($P > 0.05$ vs. vehicle), respectively (means \pm SE, $n = 4$). HU-210 also inhibited forskolin-induced cAMP formation ($\text{EC}_{50} = 145 \pm 18 \text{ nM}$, $73.0 \pm 1.5\%$ inhibition at 200 nM , $P < 0.005$), in a way reversed by rimonabant (200 nM , $82.0 \pm 6.0\%$ inhibition of HU-210 effect, $P < 0.005$, means \pm SE, $n = 3$) (data not shown). Stimulation of lipid droplets with HU-210 was also observed at d 4. In this case, the number of red-stained droplets per square millimeter was 4570 ± 350 , 8470 ± 340 , 7130 ± 190 , and 8280 ± 250 with vehicle, HU-210 ($P < 0.01$ vs. vehicle), HU-210 together with rimonabant ($P < 0.05$ vs. HU-210) and HU-210 together with SR144528 ($P > 0.05$ vs. HU-210), respectively.

Regulation of the endocannabinoid system in rat RIN-m5F β -pancreatic cells

Rat insulinoma RIN-m5F β -cells are a widely used model of pancreatic islet β -cells in as much as they release insulin

and also respond to this hormone (25). We found that they express both CB $_1$ /CB $_2$ receptors and enzymes for endocannabinoid biosynthesis and metabolism (Fig. 3, A and B). With respect to 3T3 F442A adipocytes (d 4), RIN cells expressed 2.7 ± 0.03 -fold more and 5.4 ± 0.34 -fold less CB $_1$ and CB $_2$ receptor mRNA, respectively (means \pm SE, $n = 5$), although this comparison can only be made on the assumption that different primers (for different animal species) work with similar efficacy. The expression of CB $_1$ and CB $_2$ in RIN cells was confirmed by Western immunoblots, which showed bands at approximately 83, 53, and 43 kDa for CB $_1$, and approximately 45 and 39 kDa for CB $_2$ (data not shown), in agreement with the expected sizes of the native and post-translationally modified receptors. Enzymes catalyzing anandamide biosynthesis and hydrolysis, NAPE-PLD and FAAH, and 2-AG biosynthesis and hydrolysis, DAGL- α and MAGL, were identified. Near-confluent cells at a low number of passages were kept either in "high" (25 mM) or "low"




FIG. 2. Effect of CB_1 stimulation on PPAR- γ and adiponectin expression and on lipogenesis in adipocytes. A, Effect of chronic treatment with the potent CB_1/CB_2 agonist, HU-210 (100 nM), with or without coincubation with rimonabant (SR1, 100 nM) on lipid droplet formation in differentiated adipocytes, as revealed by Oil Red-O staining and microscope observation (d 8, insulin only). Drugs were added to each change of medium, every other day, until d 8 (see *Results*). B, Effect on PPAR- γ and adiponectin expression, in differentiated and mature adipocytes (obtained with insulin only), respectively, of chronic treatment with HU-210 (100 nM), rimonabant (SR1, 100 nM), and HU-210 + rimonabant (only with PPAR- γ , because, in the case of adiponectin, rimonabant was active *per se* also at lower concentrations). Drugs were added to each change of medium, every other day, until d 8 for PPAR- γ and until d 12 for adiponectin. Expression was measured by real-time RT-PCR and is expressed as fold enhancement over vehicle. In the case of adiponectin, the results obtained after incubation with HU-210 (100 nM) until d 8 are also shown and are expressed as fold expression *vs.* the vehicle at d 12. Error bars are not shown and they were always less than or equal to 10%. SD values for cycle threshold were always less than 1%. **, ***, $P < 0.01$, 0.005 *vs.* vehicle, respectively; ##, $P < 0.01$ *vs.* HU-210 (P values were assessed as described in *Subjects and Methods*, real-time RT-PCR).

(13 mM) glucose for 24 h before stimulation with a 2-h “pulse” of 33 mM glucose, which, under both conditions, elevated both anandamide and 2-AG levels (Fig. 3, C and D). In β -cells kept on low glucose, which exhibited significantly lower endocannabinoid levels, costimulation with insulin abolished 33 mM glucose-induced endocannabinoid elevation (Fig. 3C). Conversely, in β -cells kept on high glucose to mimic hyperglycemic conditions, insulin not only did not inhibit 33 mM glucose-induced endocannabinoid elevation, but also enhanced endocannabinoid levels *per se* (Fig. 3D). Finally, under both conditions, leptin only decreased 2-AG, but not anandamide, levels and only after prolonged (24 h) stimulation (Fig. 3, C and D, and data not shown).

Effect of CB_1 stimulation on insulin release from RIN-m5F β -pancreatic cells

In β -cells kept on high glucose, but not in those kept in low glucose (data not shown; see also Ref. 19 for data in mouse β -cells), stimulation of cannabinoid receptors with HU-210 enhanced insulin release, as assessed by a specific ELISA. This effect was reversed by rimonabant but not by a cannabinoid CB_2 receptor antagonist (Fig. 3E and data not shown), and was likely due to elevation of intracellular Ca^{2+} by HU-210, which occurred within a similar range of concentrations ($EC_{50} = 260 \pm 31$ nM, $n = 3$) and was antagonized by rimonabant (Fig. 3F).

Dysregulation of endocannabinoid levels in obese mice and humans

DIO mice exhibited significantly higher ($P < 0.0005$) body weight and insulin or leptin levels than lean mice (33.5 ± 1.0 *vs.* 23.2 ± 0.3 g; 1.11 ± 0.05 *vs.* 0.59 ± 0.02 ng/ml; 15.6 ± 1.26 *vs.* 5.94 ± 0.16 ng/ml, respectively). In these mice, pancreatic anandamide and 2-AG levels were higher than in lean mice (Fig. 4A). In contrast, in a mouse model of type 1 diabetes, no significant variation of pancreatic endocannabinoid levels was observed (Fig. 4C). Furthermore, in the visceral fat of both DIO mice and obese patients, we observed a significant increase of 2-AG, but not anandamide, levels (Fig. 4, B and D). In DIO mice, a 2.5-fold enhancement of 2-AG was observed in the epididymal fat. In obese patients (Table 1), an almost 2-fold increase was observed in the visceral fat (Fig. 4D). This difference was accounted for by male (52.2 ± 0.9 pmol/g, $n = 4$, *vs.* 98.1 ± 1.2 pmol/g, $n = 9$, $P < 0.05$) rather than female patients (71.3 ± 2.0 pmol/g, $n = 6$, *vs.* 100.8 ± 2.6 pmol/g, $n = 11$, $P > 0.05$), although no statistically significant difference existed between male or female patients. No significant differences between obese and normoweight were found by real-time PCR in the expression of the mRNAs of DAGL- α (-0.1 ± 0.05 -fold in obese *vs.* normoweight, $P > 0.1$) or MAGL (1.1 ± 0.3 -fold in obese *vs.* normoweight, $P > 0.1$), suggesting that the differences in 2-AG levels might be due to different availability of biosynthetic precursors, as shown previously for the up-regulation of hypothalamic 2-AG levels in obese rodents (7). Visceral fat of obese patients





FIG. 3. Occurrence, regulation, and function of the endocannabinoid system in rat RIN-m5F β -pancreatic cells. A, Amplification profiles of CB₁ (squares), CB₂ (downward triangles), FAAH (full circles), and NAPE-PLD (upward triangles) target genes generated by real-time RT-PCR on RIN-m5F cell RNA. B, Amplification profiles of DAGL- α (upward triangles) and MAGL (full circles) target genes generated by real-time RT-PCR on RIN-m5F cell RNA. PCR efficiency was more than 92% and comparable for all the primers tested. C, Levels of endocannabinoids in RIN-m5F β -cells kept on low (13 mM) glucose for 24 h before stimulation with glucose (33 mM, 2 h), insulin (100 nM, 2 h), leptin (20 nM, 1 h), or glucose + insulin (2 h). Data are means \pm SE of $n = 6$ separate experiments. *, **, $P < 0.05$, 0.01 vs. vehicle, respectively, as assessed by ANOVA followed by the Bonferroni's test. #, Significantly different from cells grown in 25 mM glucose. D, Levels of endocannabinoids in RIN-m5F β -cells kept on high (25 mM) glucose for 24 h

FIG. 4. Dysregulation of endocannabinoid levels in obese mice and humans. A, Endocannabinoid levels in the pancreas of lean and mice with DIO. * ***, $P < 0.05$, 0.005 vs. controls, respectively, as assessed by ANOVA followed by the Bonferroni's test. B, Endocannabinoid levels in the epididymal fat of lean and DIO mice. *, $P < 0.05$ vs. controls, as assessed by ANOVA followed by the Bonferroni's test. C, Endocannabinoid levels in the pancreas of streptozotocin-treated mice, a model of type 1 diabetes. D, Endocannabinoid levels in the visceral adipose tissue of normoweight and overweight/obese humans and in the sc fat of obese patients (Table 1). **, $P \leq 0.01$ vs. visceral fat from normoweight volunteers; ##, $P < 0.01$ vs. visceral fat from obese patients as assessed by the Kuskal-Wallis nonparametric test.



also contained significantly higher 2-AG levels than sc fat ($P < 0.01$) (Fig. 4D). A trend toward decrease of CB₁ receptor levels (-1.8 ± 0.3 -fold in obese vs. normoweight, $P = 0.08$) was found in the visceral fat obese patients.

Regulation and dysregulation of endocannabinoid levels in human blood during hyperglycemia

To assess whether a transient hyperglycemia, immediately corrected by a well-functioning insulin, results in decreased serum endocannabinoid levels, we measured the serum endocannabinoid levels in 12 normoweight adults 1 h before (preprandial) and after the meal (postprandial), respectively, when insulin levels increase from 4.02 ± 0.63 to 25.2 ± 6.47 mU/ml (means \pm SE, $P < 0.005$). We observed a strong decrease of blood anandamide levels in postprandial volun-

teers (Fig. 5A). In a second experiment, we decided to evaluate whether a noncorrected hyperglycemia, due to a pathological condition, results in increased serum endocannabinoid levels. We used overweight male and female individuals with type 2 diabetes under randomized pharmacological treatments and whose only common clinical features were hyperglycemia of approximately 10 mmol/liter, age of approximately 69 yr, and BMI of approximately 33 kg/m² (Table 2). In this case, we detected higher circulating levels of both anandamide and 2-AG in diabetic patients than in healthy patients (Fig. 5B).

Discussion

The findings reported in this study indicate that a dysregulated endocannabinoid system in the adipocytes and

before stimulation with glucose (33 mM, 2 h), insulin (100 nM, 2 h), leptin (20 nM, 1 h), or glucose + insulin (2 h). Data are means \pm SE of $n = 6$ –9 separate experiments. *, **, ***, $P < 0.05$, 0.01 , 0.005 vs. vehicle, respectively; #, $P < 0.05$ vs. vehicle of cells grown in high (13 mM) glucose, as assessed by ANOVA followed by the Bonferroni's test (see C). Note that low, high, and very high glucose do not refer to, nor do they reflect, the fasting concentrations of glucose occurring in humans during normo- or hyperglycemia, respectively. They refer instead to the optimal culturing conditions of RIN-m5F β -cells, which the manufacturer advises to grow in 25 mM glucose. E, Effect of 2 h of stimulation with HU-210 (200 nM), HU-210 + rimonabant (SR1, 1 μ M), or HU-210 + SR144528 (SR2, 1 μ M, a selective CB₂ antagonist) on insulin release from RIN-m5F β -cells kept on high (25 mM) glucose for 24 h. Insulin was measured using an established ELISA. *, **, $P < 0.05$, 0.01 vs. vehicle, respectively; ##, $P < 0.01$ vs. HU-210, as assessed by ANOVA followed by the Bonferroni's test. F, Effect of HU-210 on intracellular Ca²⁺ in RIN-m5F β -cells kept on high (25 mM) glucose for 24 h before stimulation. The effect of increasing concentrations of HU-210, measured with Fluo-4, 30 sec after administration, when the effect reaches a plateau before decreasing, is reported as the percentage of the maximal effect caused by ionomycin (4 μ M), given to cells after HU-210. Similar potency was observed with HU-210 when the experiment was performed in the absence of extracellular Ca²⁺ and with Fura-2. F, inset, Effect of SR1 (200 nM) on HU-210 (1 μ M)-induced effect on intracellular Ca²⁺. The results are expressed as the percentage of the effect observed with HU-210 (1 μ M) alone. Data are means \pm SE of $n = 3$ separate experiments. **, $P < 0.01$, vs. HU-210 only, as assessed by ANOVA followed by the Bonferroni's test.




FIG. 5. Dysregulation of blood endocannabinoid levels in hyperglycemia. A, Serum endocannabinoid levels in postprandial *vs.* preprandial healthy normoweight volunteers. Blood sampling was carried out 1 h before and after the meal, respectively. B, Serum endocannabinoid levels in overweight type 2 diabetes *vs.* healthy volunteers. This experiment was designed uniquely to assess whether a noncorrected hyperglycemia, due to a pathological condition, results in increased serum endocannabinoid levels. For this reason, we purposely used male and female patients with type 2 diabetes under randomized pharmacological treatments and whose only common clinical features were hyperglycemia approximately 1.85 g/liter, age approximately 65, and BMI approximately 30 (Table 2). **, ***, $P < 0.01, 0.005$ *vs.* controls, respectively, as assessed by the Kuskal-Wallis nonparametric test (B) or the two-tailed paired Student's test (A).

β -cells might contribute to hyperlipidemia, hypoadiponectinemia, and hyperinsulinemia in obesity (26), and explain why CB_1 receptor blockade reduces these metabolic parameters in obese individuals independently not only from inhibition of food intake but also, in part, of body weight loss (27–29).

The data obtained in our model of adipocytes suggest that the endocannabinoid system is up-regulated immediately before adipocyte differentiation, possibly to concur at inducing differentiation and (also via CB_1 -mediated inhibition of cAMP formation) lipogenesis. Endocannabinoids might then be “turned off” by leptin, which is produced by mature adipocytes and was shown here to efficaciously reduce both anandamide and 2-AG levels, and in part by PPAR- γ , which lowers 2-AG levels, although only in the early phase of adipocyte differentiation. However, in the continued presence of insulin, as during the hyperinsulinemia typical of obesity, adipocytes become hypertrophic and still contain high levels not only of CB_1 receptors, but also of 2-AG, because of the sustained expression of the major 2-AG biosynthesizing enzyme (and possibly also due to loss of inhibition by PPAR- γ). Only under these conditions, overstimulation of CB_1 receptors depresses the expression of a late marker of differentiation, adiponectin [as suggested here and previously (17, 30)], thereby contributing to the metabolic consequences of obesity (18) and explaining why blockade of CB_1 receptors restores in DIO mice a lean phenotype in terms of expression of adiponectin-dependent enzymes involved in lipid and glucose metabolism (31). There is a temporal separation between the effect of CB_1 stimulation on PPAR- γ and adiponectin (Fig. 2B). Therefore, although adiponectin expression is under the positive control of PPAR- γ , it is likely that the effect on adiponectin is independent from that on PPAR- γ . Accordingly, Gary-Bobo *et al.* (30) showed that a CB_1 antagonist does not induce lipid droplet formation in 3T3 adipocytes but still up-regulates late markers of differentiation.

In a model of pancreatic islet β -cells, we found that conditions mimicking hyperglycemia also lead to dysregulation of endocannabinoid signaling. A “very high” concentration of glucose always elevates the levels of both anandamide and 2-AG in these cells, whereas leptin is a much less efficacious inhibitor of endocannabinoid levels in these cells than in adipocytes. However, whereas in cells grown in low glucose, insulin reduces the glucose-induced elevation of endocannabinoid levels and has no effect *per se*, in β -cells kept in high glucose, endocannabinoid levels are not depressed any longer by insulin, which instead elevates both anandamide and 2-AG levels *per se*. Altogether, these data suggest that under conditions of hyperglycemia, such as during prediabetes, type 2 diabetes, and obesity, the endocannabinoid system in β -cells, instead of remaining under insulin control, becomes dysregulated. The consequent overstimulation of CB_1 receptors might reinforce insulin release—as shown here with HU-210—and cause permanent hyperinsulinemia. This, in turn, would: 1) start a vicious circle and further elevate endocannabinoid levels in β -cells, and 2) trigger adipocyte hypertrophy and endocannabinoid hyperactivity in adipocytes, with subsequent increase in lipid levels, decrease in adiponectin levels, and their metabolic consequences (supplemental Fig. 1, published on The Endocrine Society's Journals Online web site at <http://jcem.endojournals.org>).

As previously observed in the brain (32, 33), peripheral anandamide and 2-AG levels are regulated in different ways by the same stimuli. This is not surprising in consideration of the fact that these compounds are biosynthesized and metabolized via different pathways (1, 2). For example, leptin controls the levels of anandamide through regulation of FAAH, and of 2-AG through regulation of the levels of its biosynthetic precursor (7, 23, 24). The differential regulation of endocannabinoid levels during adipocyte differentiation is also not surprising in view of findings in other differentiating cells or organs (33, 34).

The up-regulation of the levels of 2-AG in adipocytes, and

of both endocannabinoids in β -cells, observed here under conditions of hyperinsulinemia/hyperglycemia, correspond to the scenario found *in vivo* in mice with DIO, where the levels of 2-AG were 2.5-fold higher in epididymal fat, and of both endocannabinoids were doubled in the pancreas, compared with lean mice. Conversely, no change in endocannabinoid levels was observed in the pancreas from streptozotocin-treated mice, an animal model of type 1 diabetes, indicating that, in this organ, endocannabinoid up-regulation is not simply due to islet β -cell malfunctioning. An almost 2-fold elevation of 2-AG, but not anandamide, levels was observed also in the visceral adipose tissue of overweight/obese patients with mild hyperglycemia compared with normoweight controls. In these patients, visceral fat contained significantly higher levels of 2-AG than sc fat, thus emphasizing the potential implication of the endocannabinoid system in the link between the metabolic syndrome and visceral, but not sc, adiposity (26). As 2-AG is significantly more efficacious than anandamide at CB₁ receptors (1), this up-regulation is likely to cause a significant elevation of adipocyte CB₁ receptor activity during obesity, thus possibly explaining the weight loss-independent effects of rimonabant on adiponectin levels (27).

The dysregulation of endocannabinoid levels in the adipose tissue and pancreas shown here, and previously in the liver (14), to be a hallmark of obesity may also concern other organs involved in the control of energy balance, as suggested by the recent finding of a strong correlation between human obesity and genetic malfunctioning of anandamide degradation (35). Therefore, higher endocannabinoid levels might be found also in the blood, as recently shown for obese *vs.* normoweight women (36, 37). Here we assessed whether conditions leading to immediately corrected *vs.* permanently altered glycaemia, due to well- or ill-functioning of insulin signaling, respectively, are accompanied by altered blood endocannabinoid levels. Healthy volunteers fasted for 12 h and then receiving a meal inducing a strong increase in insulinemia, exhibited blood anandamide levels significantly lower than preprandial levels. In contrast, overweight patients with hyperglycemia caused by type 2 diabetes exhibited blood endocannabinoid levels significantly higher than those of age- and BMI-matched normoglycemic volunteers. These findings might suggest that normal regulation of blood endocannabinoid levels is disrupted in hyperglycemic patients, perhaps in the same way as we have observed here in β -cells grown in high glucose. The fact that, because of ethical reasons, we could not include untreated type 2 diabetes patients is a limitation of this experiment. However, because we wanted to investigate whether permanent as opposed to transient hyperglycemia causes different changes in endocannabinoid levels, we included patients under randomized treatments to avoid biasing of results from the type of treatment.

In conclusion, we have shown that endocannabinoid/CB₁ signaling: 1) participates in adipocyte differentiation and lipid accumulation, and remains activated in mature adipocytes, where it causes depression of adiponectin expression; 2) stimulates insulin secretion in RIN-m5F β -cells and, in turn, is stimulated by insulin under conditions mimicking hyperglycemia; and 3) is overactive in the adipose tissue and

pancreas of mice with DIO, a condition similar to human obesity, and in the visceral adipose tissue of obese patients. These findings provide further evidence to the hypothesis that endocannabinoids play a direct role in the peripheral control of energy homeostasis.

Acknowledgments

We are grateful to Prof. Angelo Izzo (Department of Pharmacology, Faculty of Pharmacy, University of Naples "Federico II") for providing tissues from mice treated with streptozotocin, to Prof. Ludovico Docimo (Clinica Chirurgica Generale e Chirurgia d'Urgenza) and Prof. Mario Verza (Dipartimento di Gerontologia, Geriatria e Malattie del Metabolismo, Second University of Naples) for providing samples of visceral and sc fat, and to Drs. Tiziana Bisogno and Marta Valenti (Endocannabinoid Research Group, Consiglio Nazionale delle Ricerche, Italy) for help in cAMP assays and in mass spectrometry analyses.

Received December 9, 2005. Accepted May 2, 2006.

Address all correspondence and requests for reprints to: Vincenzo Di Marzo, Ph.D., Endocannabinoid Research Group, Institute of Biomolecular Chemistry of the National Research Council, via Campi Flegrei 34, 80078 Pozzuoli (NA), Italy. E-mail: vdimarzo@icmib.na.cnr.it

The study was partly supported by the Italian National Research Council, by a research grant from Sanofi-Aventis (to V.D.M.), and by a grant from the Sixth EC Program (LSHM-CT-2003-503041 to U.P.).

I.M., M.-P.G., P.O., V.M., L.D.P., C.C., S.P., L.H., F.F., R.P., R.R., M.M., and P.M. have nothing to declare. U.P. and V.D.M. received lecture fees or are on a paid advisory board. V.D.M. received grant support (April 2004 to April 2006).

References

1. Di Marzo V, Bifulco M, De Petrocellis L 2004 The endocannabinoid system and its therapeutic exploitation. *Nat Rev Drug Discov* 3:771–784
2. Di Marzo V, Matias I 2005 Endocannabinoid control of food intake and energy balance. *Nat Neurosci* 8:585–589
3. Vickers SP, Kennett GA 2005 Cannabinoids and the regulation of ingestive behaviour. *Curr Drug Targets* 6:215–223
4. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL 1998 Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. *Life Sci* 63:PL113–PL117.
5. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA 2003 Preferential effects of the cannabinoid CB₁ receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. *Psychopharmacology (Berl)* 167:103–111
6. Chambers AP, Sharkey KA, Koopmans HS 2004 Cannabinoid (CB)₁ receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. *Physiol Behav* 82:863–869
7. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G 2001 Leptin-regulated endocannabinoids are involved in maintaining food intake. *Nature* 410:822–825
8. Kirkham TC, Williams CM, Fezza F, Di Marzo V 2002 Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. *Br J Pharmacol* 136:550–557
9. Williams CM, Kirkham TC 1999 Anandamide induces overeating: mediation by central cannabinoid (CB₁) receptors. *Psychopharmacology (Berl)* 143:315–317
10. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie PC 2003 Anti-obesity effect of SR141716, a CB₁ receptor antagonist, in diet-induced obese mice. *Am J Physiol Regul Integr Comp Physiol* 284:R345–R353
11. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, Janiak P, Herbert JM 2005 The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. *Diabetes Obes Metab* 7:65–72
12. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P 2004 CB₁ cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. *Int J Obes Relat Metab Disord* 28:640–648
13. Cota D, Marsicano G, Tschöp M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortman S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U 2003 The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. *J Clin Invest* 112:423–431
14. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G 2005 Endocannabinoid

- activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. *J Clin Invest* 115:1298–1305
15. **National Cholesterol Education Program** 2001 Detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Bethesda, MD: National Institutes of Health
 16. **Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group** 2005 Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. *Lancet* 365:1389–1397
 17. **Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P** 2003 The cannabinoid CB1 receptor antagonist SR141716 increases Acp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. *Mol Pharmacol* 63:908–914
 18. **Staiger H, Haring HU** 2005 Adipocytokines: fat-derived humoral mediators of metabolic homeostasis. *Exp Clin Endocrinol Diabetes* 113:67–79
 19. **Juan-Pico P, Fuentes E, Javier Bermudez-Silva F, Javier Diaz-Molina F, Ripoll C, Rodriguez de Fonseca F, Nadal A** 2006 Cannabinoid receptors regulate Ca²⁺ signals and insulin secretion in pancreatic β -cell. *Cell Calcium* 39:155–162
 20. **Ramirez ZJL, Castro MF, Kuri HW** 1992 Quantitation of adipose conversion and triglycerides by staining intra-cytoplasmic lipids with Oil Red O. *Histochemistry* 97:493–497
 21. **Nakhoda A, Wong HA** 1979 The induction of diabetes in rats by intramuscular administration of streptozotocin. *Experientia* 35:1679–1680
 22. **De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V** 2003 Endocannabinoid signalling in the blood of patients with schizophrenia. *Lipids Health Dis* 2:1–9
 23. **Maccarrone M, Bari M, Di Rienzo M, Finazzi-Agro A, Rossi A** 2003 Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin. *J Biol Chem* 278:32726–32732
 24. **Maccarrone M, Fride E, Bisogno T, Bari M, Cascio MG, Battista N, Finazzi Agro A, Suris R, Mechoulam R, Di Marzo V** 2005 Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. *Mol Hum Reprod* 11:21–28
 25. **Hohmeier HE, Newgard CB** 2004 Cell lines derived from pancreatic islets. *Mol Cell Endocrinol* 228:121–128
 26. **Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A, Lemieux I, Despres JP** 2005 Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. *J Clin Endocrinol Metab* 90:1434–1439
 27. **Després JP, Golay A, Sjostrom L, the RIO-Lipids Study Group**, One-year treatment with rimonabant increases plasma adiponectin levels beyond weight loss: the RIO-Lipids trial. 65th Scientific Sessions of the American Diabetes Association, San Diego, CA, 2005 (Abstract 7-LB)
 28. **Rosenstock J**, The potential of rimonabant in prediabetes: pooled 1-year results from RIO-Lipids, RIO-Europe and RIO-North America studies. 65th Scientific Sessions of the American Diabetes Association, San Diego, CA, 2005, (Abstract 13-LB)
 29. **Després JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group** 2005 Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. *N Engl J Med* 353:2121–2134
 30. **Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M** 2006 The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. *Mol Pharmacol* 69:471–478
 31. **Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galiegue S, Casellas P** 2005 The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. *FASEB J* 19:1567–1569
 32. **Valenti M, Vigano D, Cascio MG, Rubino T, Steardo L, Parolaro D, Di Marzo V** 2004 Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. *Cell Mol Life Sci* 61:945–950
 33. **Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernandez-Ruiz JJ** 1999 Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. *Synapse* 33:181–191
 34. **Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A, Finazzi-Agro A** 2003 The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. *J Biol Chem* 278:33896–33903
 35. **Sipe JC, Waalen J, Gerber A, Beutler E** 2005 Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). *Int J Obes Relat Metab Disord* 29:755–759
 36. **Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V** 2005 Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. *Neuropsychopharmacology* 30:1216–1221
 37. **Engeli S, Janke J, Gorzelniak K, Bohnke J, Ghose N, Lindschau C, Luft FC, Sharma AM** 2005 Activation of the peripheral endocannabinoid system in human obesity. *Diabetes* 54:2838–2843

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.